In regarding Owlstone Medical's breathtaking Breath Biopsy program - Here's my Crystal Ball Theory:
The appointment of Dr. Richard Yost to the advisory board of Owlstone Medical is going to playout to either be exceptionally good for both Cannabix and Algernon or exceptionally destructive for our FAIMS devices overall (Controlled Substances and Diseases). I view Owlstone Medical as direct competition to Algernon for sure. Yost has time to advise Owlstone but does not have time to clearly demonstrate where we are in the process for both companies. All I know is the devices are now tucked away in Yost's classroom with no end in sight to completion - IF EVER. Meanwhile, Algernon has made a hard turn (Hallelujua!) towards pharmaceuticals which I believe will at least get shareholders back to even post split. It's also my hope Algernon truly has a winner on it's hands in comparison to ALL other companies in the Bullrun Capital portfolio to date. IMO, none of which has shown significant success to date. Great runs - yes. A real world product with a contract or two - yes. However, none have broken through as legitimate revenue streams/business models beyond selling shares. Will Cannabix ever get to commercialization with it's THC breathalyzer? I don't know, but IMO the patent situation is very very concerning moving forward >>> How do you launch a product without patent protections? Other scientists have directly made claims in their patent application, of all places, that the FAIMS science is insufficient to detect THC. What does Yost have to publicly say about that? Maybe we should contact Owlstione Medical to contact Yost to provide common shareholders with some concrete answers? I mean there are red flags popping up that cannot be denied. If the sh*t is going belly up, this is a terrible way for Cannabix to go out.
News 
Market Data 
Discover 
